Full-Service Global Support for COVID-19 Studies

  • Post author:
  • Post category:

Our broad expertise, end-to-end services and ability to begin immediate collaboration with government, commercial and academic partners in more than 60 countries make us uniquely positioned to support the COVID-19 response. We address emerging pandemics, epidemics and outbreaks with expertise that supports health and research efforts globally. We are experienced in addressing the complex aspects of infectious diseases — from infection prevention and control to clinical research on diagnostics, vaccines and treatment.

Continue ReadingFull-Service Global Support for COVID-19 Studies

Coronaviruses Fact Sheet

  • Post author:
  • Post category:

Discovered in the 1960s, coronaviruses (CoV) are a large group of RNA viruses in the family Coronaviridae that cause disease in humans and animal species. Human illness includes respiratory infections that range from the common cold to viral (direct) or bacterial (indirect) pneumonia and are especially serious in infants and at-risk adults. There are seven known coronavirus types/strains.

Continue ReadingCoronaviruses Fact Sheet

About the PREVAIL Network

  • Post author:
  • Post category:

The Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL) network was established through a partnership between local Liberian and international partners, including the U.S. National Institutes of Health, World Health Organization and FHI Clinical, to provide sustainable research infrastructure to address diseases of public health importance.

Continue ReadingAbout the PREVAIL Network

How Can We Streamline the Vaccine Development Process?

  • Post author:
  • Post category:

To address the urgency of vaccine development during a pandemic, innovative strategies are implemented across study design, regulatory processes, recruitment process and more. In this e-book, we describe some of those innovations and argue for incorporating these into the fabric of clinical trials — to establish a “new normal.”

Continue ReadingHow Can We Streamline the Vaccine Development Process?